Safety overview and management of inavolisib alone and in combination therapies in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer (GO39374)
inavolisib 单药及联合疗法在 PIK3CA 突变、HR 阳性、HER2 阴性晚期乳腺癌中的安全性概述及管理 (GO39374)
期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105303
Gambardella, V; Accordino, M K; Bedard, P L; Cervantes, A; Hamilton, E; Italiano, A; Kalinsky, K; Krop, I E; Oliveira, M; Saura, C; Schmid, P; Turner, N C; Varga, A; Fernandez-Saranillo, A; Jin, Y; Royer-Joo, S; Peters, U; Shankar, N; Schutzman, J L; Juric, D; Jhaveri, K L